Michela Deleidi studied medicine at Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. She completed her residency in neurology followed by a fellowship at Harvard Medical School. She focused on pluripotent stem cell technology for Parkinson’s disease (PD) modeling and regenerative medicine applications. She was awarded an Alexander von Humboldt Fellowship and she relocated to Germany to pursue her PhD studies at the DZNE in Tübingen. By combining cellular reprogramming with genome editing, her work led to one of the first stem cell-based models of PD, clearly showing a mechanistic link with lysosomal storage diseases. Since 2016, Michela Deleidi is a Helmholtz Young Investigator at DZNE and an assistant professor of Neurology at the University of Tübingen. In 2023, Michela Deleidi moved to be a Group Leader at the Institute Imagine in Paris where she leads the Mechanisms of Therapy of Genetic Brain Diseases division.
Co-PI (Core Leadership)
Michela Deleidi, MD, PhD
Institut Imagine
Michela Deleidi studied medicine at Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. She completed her residency in neurology followed by a fellowship at Harvard Medical School. She focused on pluripotent stem cell technology for Parkinson’s disease (PD) modeling and regenerative medicine applications. She was awarded an Alexander von Humboldt Fellowship and she relocated to Germany to pursue her PhD studies at the DZNE in Tübingen. By combining cellular reprogramming with genome editing, her work led to one of the first stem cell-based models of PD, clearly showing a mechanistic link with lysosomal storage diseases. Since 2016, Michela Deleidi is a Helmholtz Young Investigator at DZNE and an assistant professor of Neurology at the University of Tübingen. In 2023, Michela Deleidi moved to be a Group Leader at the Institute Imagine in Paris where she leads the Mechanisms of Therapy of Genetic Brain Diseases division.
